Dr. Matthew S. Markert, MD, PhD

Dr. Markert practices at California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD in San Francisco, California.

Dr. Markert's NPI, 1073951539, was assigned on June 6, 2013. Dr. Markert graduated from University of Miami, Miller School of Medicine in 2013. Dr. Markert holds California license A149300.

Dr. Markert's primary practice is California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD, at 2333 Buchanan St, San Francisco, CA 94115.

Dr. Markert's primary practice is California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD in San Francisco, California. Dr. Markert is also affiliated with California Pacific Medical Center Van Ness Campus. The medical group on file is Palo Alto Foundation Medical Group. Dmand AI also links Dr. Markert to 8 more hospitals, 23 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Markert practices, 12 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Markert's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Markert is board certified in epilepsy by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Markert's licenses on file in 15 states: California, Maine, New York, West Virginia, Florida, Idaho, Illinois, Michigan, Ohio, Pennsylvania, Virginia, Connecticut, Georgia, Louisiana and Massachusetts.

Dmand AI lists alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, epilepsy, essential tremor, fibromyalgia and chronic pain, head injury and hereditary polyneuropathy among the conditions Dr. Markert treats.

CMS data shows 5,822 Medicare services from Dr. Markert across 16 procedure codes in 2024, for 414 Medicare patients. Medicare paid $85,882 for them.

CMS counts 414 Medicare patients who saw Dr. Markert in 2024. The largest group is 65 to 74, with 161 patients. 73% of them have high blood pressure, and 69% have high cholesterol. 29% are also on Medicaid. Their average risk score is 1.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Markert's median patient age at 62, with 54% women.

In 2024, Dr. Markert wrote 2,139 Medicare Part D claims for 387 patients. 92% of them were for generic drugs. CMS names the drug for 1,888 of them, across 47 drugs with 11 or more claims each, at $186,318 in total drug cost. In 2023, CMS named 2,194 claims across 55 drugs.

Dr. Markert accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Markert as offering telehealth.

Dmand AI links 21 papers to Dr. Markert, published from 2011 to 2020. 2011 was the busiest year, with 5. The most frequent topics are Carotid Arteries, Vascular Diseases and Carotid Artery Diseases. Dr. Markert's most frequent co-authors are Mitchell S. Elkind, MD, Clinton Wright, MD and Josef Parvizi, MD, PhD.

CMS Open Payments shows 62 general payments to Dr. Markert from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 97% of the total. Ceribell, Inc. paid the most, $125,255.

Dr. Markert graduated from University of Miami, Miller School of Medicine in 2013.

Dr. Markert is in network with 27 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 15. Check the plan with the practice before a visit.